Celladon Corporation (NASDAQ:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, on 07 July 2014 announced that it has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart … Continue reading Active Watch List – Celladon Corp (NASDAQ:CLDN), World Acceptance Corp. (NASDAQ:WRLD) , Associated Banc Corp (NASDAQ:ASBC) , NN, Inc. (NASDAQ:NNBR)